Meta-analysis of statins in chronic kidney disease: Who benefits?

Meta-analysis of statins in chronic kidney disease: Who benefits?
QJM: An International Journal of Medicine — Messow CM, et al. | March 20, 2017

sponsor
Analysts decide the extent to which the adequacy of statins varies by kidney class. Statins are shown in stage 3 chronic kidney disease (CKD), probably demonstrated in CKD4, not showed in CKD5/5D and probably showed in patients with a functioning transplant. Too few patients with CKD4 and renal transplants have been included in lipid lowering trials for confident conclusions to be drawn.

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *